The word “antitrust” may soon become a part of VCs’ daily vocabulary, without necessarily having anything to do with price fixing, bid rigging, or market allocation. This is because proposed changes to Hart-Scott-Rodino reportability requirements, congressional pressure to modify existing antitrust laws, heightened antitrust scrutiny on the tech and life sciences sectors, and other developments in the antitrust regulatory framework will impact many VCs and their portfolio companies.
Join this discussion hosted by the National Venture Capital Association (NVCA) and led by Zarema A. Jaramillo, Partner, Antitrust/Competition and Managing Partner, Washington, D.C. Office and Meredith Beuchaw, Partner, Venture Capital and Tech Mergers & Acquisitions to learn more about how these issues may impact your fund and portfolio.
Time: 1-2 p.m. ET
